Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALIM NASDAQ:LXRX NASDAQ:RGLS NASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALIMAlimera Sciences$5.54$5.55$2.61▼$5.65$290.24M1.25376,318 shsN/ALXRXLexicon Pharmaceuticals$1.40+4.5%$1.14$0.28▼$2.18$508.76M1.262.26 million shs3.55 million shsRGLSRegulus Therapeutics$8.16$8.10$0.83▼$8.35$564.92M0.351.02 million shsN/AXOMAXOMA Royalty$36.68+2.7%$31.94$18.35▼$38.48$443.46M0.9852,175 shs30,056 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALIMAlimera Sciences0.00%0.00%0.00%0.00%0.00%LXRXLexicon Pharmaceuticals0.00%+17.65%+27.27%+48.04%-12.50%RGLSRegulus Therapeutics0.00%0.00%0.00%0.00%+406.83%XOMAXOMA Royalty0.00%-0.05%+12.97%+45.56%+41.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALIMAlimera Sciences$5.54$5.55$2.61▼$5.65$290.24M1.25376,318 shsN/ALXRXLexicon Pharmaceuticals$1.40+4.5%$1.14$0.28▼$2.18$508.76M1.262.26 million shs3.55 million shsRGLSRegulus Therapeutics$8.16$8.10$0.83▼$8.35$564.92M0.351.02 million shsN/AXOMAXOMA Royalty$36.68+2.7%$31.94$18.35▼$38.48$443.46M0.9852,175 shs30,056 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALIMAlimera Sciences0.00%0.00%0.00%0.00%0.00%LXRXLexicon Pharmaceuticals0.00%+17.65%+27.27%+48.04%-12.50%RGLSRegulus Therapeutics0.00%0.00%0.00%0.00%+406.83%XOMAXOMA Royalty0.00%-0.05%+12.97%+45.56%+41.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALIMAlimera Sciences 0.00N/AN/AN/ALXRXLexicon Pharmaceuticals 2.50Moderate Buy$3.23130.36% UpsideRGLSRegulus Therapeutics 2.17Hold$8.807.84% UpsideXOMAXOMA Royalty 3.33Buy$69.5089.48% UpsideCurrent Analyst Ratings BreakdownLatest RGLS, ALIM, LXRX, and XOMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025XOMAXOMA RoyaltyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/2/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.008/12/2025XOMAXOMA RoyaltyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/7/2025LXRXLexicon PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.20 ➝ $1.90(Data available from 9/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALIMAlimera Sciences$99.68M2.91N/AN/A$0.88 per share6.30LXRXLexicon Pharmaceuticals$31.08M16.37N/AN/A$0.40 per share3.50RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.17 per shareN/AXOMAXOMA Royalty$28.49M15.57N/AN/A$6.95 per share5.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALIMAlimera Sciences-$20.13M-$1.57N/A26.38N/A-14.74%-33.70%-9.63%N/ALXRXLexicon Pharmaceuticals-$200.40M-$0.33N/AN/AN/A-206.43%-83.63%-42.22%11/11/2025 (Estimated)RGLSRegulus Therapeutics-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%N/AXOMAXOMA Royalty-$13.82M-$1.55N/AN/AN/A-27.57%2.63%0.97%11/6/2025 (Estimated)Latest RGLS, ALIM, LXRX, and XOMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025XOMAXOMA Royalty-$0.12$0.48+$0.60$0.44$9.39 million$13.13 million8/6/2025Q2 2025LXRXLexicon Pharmaceuticals-$0.08$0.01+$0.09$0.01$4.87 million$28.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALIMAlimera SciencesN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALIMAlimera Sciences1.802.792.62LXRXLexicon Pharmaceuticals0.434.164.16RGLSRegulus TherapeuticsN/A16.3116.31XOMAXOMA Royalty1.414.884.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALIMAlimera Sciences99.83%LXRXLexicon Pharmaceuticals74.70%RGLSRegulus Therapeutics92.38%XOMAXOMA Royalty95.92%Insider OwnershipCompanyInsider OwnershipALIMAlimera Sciences31.40%LXRXLexicon Pharmaceuticals13.90%RGLSRegulus Therapeutics4.35%XOMAXOMA Royalty7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALIMAlimera Sciences15052.39 million35.94 millionOptionableLXRXLexicon Pharmaceuticals140363.40 million312.89 millionOptionableRGLSRegulus Therapeutics3069.23 million66.22 millionOptionableXOMAXOMA Royalty1012.09 million11.22 millionOptionableRGLS, ALIM, LXRX, and XOMA HeadlinesRecent News About These CompaniesGoldman Sachs Group Inc. Sells 9,447 Shares of XOMA Royalty Corporation $XOMA2 hours ago | marketbeat.comEssa Pharma Agrees to Amend Terms to be Acquired by XenoTherapeuticsSeptember 24, 2025 | marketwatch.comESSA Pharma cuts shareholder payout in revised Xeno dealSeptember 24, 2025 | msn.comESSA Pharma Inc. Amends Agreement with XenoTherapeuticsSeptember 24, 2025 | prnewswire.comInsider Selling: XOMA Royalty (NASDAQ:XOMA) CFO Sells 4,330 Shares of StockSeptember 24, 2025 | insidertrades.comMural Oncology plc Publishes Definitive Proxy Statement for Acquisition by XOMA Royalty CorporationSeptember 23, 2025 | quiverquant.comQXOMA Royalty (NASDAQ:XOMA) CFO Sells $155,836.70 in StockSeptember 23, 2025 | marketbeat.comMural Oncology Plc Announces Acquisition by XOMA Royalty CorporationSeptember 23, 2025 | tipranks.comInsider Sale: SVP of $XOMA Sells 15 SharesSeptember 23, 2025 | quiverquant.comQXoma Completes Acquisition of HilleVaxSeptember 23, 2025 | tipranks.comXOMA Royalty Declares Quarterly Preferred Stock DividendsSeptember 22, 2025 | globenewswire.comXOMA Royalty (NASDAQ:XOMA) Stock Crosses Above 200 Day Moving Average - Here's WhySeptember 20, 2025 | marketbeat.comDoes XOMA Royalty (XOMA) Have the Potential to Rally 85.34% as Wall Street Analysts Expect?September 19, 2025 | zacks.comXoma announces closing of tender offer for HilleVaxSeptember 17, 2025 | msn.comHilleVax Acquired by XOMA, Delisting from NasdaqSeptember 17, 2025 | tipranks.comXOMA Royalty Corporation Completes Tender Offer for HilleVax, Inc. Shares and Merger FinalizedSeptember 17, 2025 | quiverquant.comQXOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.September 17, 2025 | globenewswire.comXOMA Royalty (NASDAQ:XOMA) Upgraded to Strong-Buy at Zacks ResearchSeptember 14, 2025 | marketbeat.comThe Pharma Letter M&A roundup - August 2025September 9, 2025 | thepharmaletter.comTNuveen LLC Invests $286,000 in XOMA Royalty Corporation $XOMASeptember 8, 2025 | marketbeat.comXOMA Royalty Corporation $XOMA Shares Sold by BVF Inc. ILSeptember 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRGLS, ALIM, LXRX, and XOMA Company DescriptionsAlimera Sciences NASDAQ:ALIMAlimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.Lexicon Pharmaceuticals NASDAQ:LXRX$1.40 +0.06 (+4.48%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$1.36 -0.04 (-2.86%) As of 04:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Regulus Therapeutics NASDAQ:RGLSRegulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.XOMA Royalty NASDAQ:XOMA$36.68 +0.97 (+2.72%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$36.85 +0.17 (+0.48%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/22 - 09/26 Get Exposure to Millennials' Purchasing Power With This ETF Beam Global Gets Buy Rating With 101% Upside Potential Institutional Buying Sets a High Floor for Microsoft Stock High-Momentum ETFs to Mine for Gold, Silver, and Bitcoin It's a Good Time to Build a Position in KB Home Alphabet: Time to Take Profits, Buy, or Wait for a Pullback? NuScale, Rocket Lab Face Heavy Insider Selling After Surges Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
